Skip Navigation



JAC Advance Access published online on February 18, 2005
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dki042
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
55/4/413    most recent
dki042v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lucas, G. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lucas, G. M.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

JAC © The British Society for Antimicrobial Chemotherapy 2005; all rights reserved

Original article

Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven

Gregory M. Lucas 1*

1 Johns Hopkins University, Baltimore, MD 21287, USA

* To whom correspondence should be addressed.
Gregory M. Lucas, E-mail: glucas{at}jhmi.edu


  Abstract

The clinical goals of HIV treatment are optimally accomplished through consistent high-level adherence to highly active antiretroviral therapy (HAART) and durable suppression of the viral load. However, as a result of the need for lifelong therapy and HIV's prodigious replication rate and error-prone reverse transcriptase, varying amounts of antiretroviral drug resistance are common in treated individuals. Medication adherence is linked to the development of drug resistance, although not by a simple linear relationship. Recent studies have suggested that extensive drug resistance is not a major determinant of HIV disease progression and death. Rather, failure to access care and discontinuation of or non-adherence with therapy are arguably the most important factors associated with HIV disease progression in the HAART era. Other data indicate that continued therapy in the setting of extensive drug resistance and the inability to achieve viral suppression can provide continued clinical benefit. Such benefit may be mediated, at least partially, by reductions in viral fitness associated with drug resistance mutations.

Keywords: HAART; highly active antiretroviral therapy; treatment.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
T. L. Kieffer, A. D. Kwong, and G. R. Picchio
Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)
J. Antimicrob. Chemother., November 10, 2009; (2009) dkp388v1.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
F. J. Palella Jr., C. Armon, K. Buchacz, S. R. Cole, J. S. Chmiel, R. M. Novak, K. Wood, A. C. Moorman, J. T. Brooks, and for the HOPS (HIV Outpatient Study) Investigators
The Association of HIV Susceptibility Testing With Survival Among HIV-Infected Patients Receiving Antiretroviral Therapy: A Cohort Study
Ann Intern Med, July 21, 2009; 151(2): 73 - 84.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
T. Miura, M. A. Brockman, Z. L. Brumme, C. J. Brumme, F. Pereyra, A. Trocha, B. L. Block, A. Schneidewind, T. M. Allen, D. Heckerman, et al.
HLA-Associated Alterations in Replication Capacity of Chimeric NL4-3 Viruses Carrying gag-protease from Elite Controllers of Human Immunodeficiency Virus Type 1
J. Virol., January 1, 2009; 83(1): 140 - 149.
[Abstract] [Full Text] [PDF]

Home page
 J Int Assoc Physicians AIDS Care (Chic Ill)Home page
S. J. Fielden, M. L. A. Rusch, B. Yip, E. Wood, K. Shannon, A. R. Levy, J. S. G. Montaner, and R. S. Hogg
Nonadherence Increases the Risk of Hospitalization Among HIV-Infected Antiretroviral Naive Patients Started on HAART
J Int Assoc Physicians AIDS Care (Chic Ill), September 1, 2008; 7(5): 238 - 244.
[Abstract] [PDF]

Home page
 J. Virol.Home page
L. Buonaguro, M. L. Tornesello, and F. M. Buonaguro
Human Immunodeficiency Virus Type 1 Subtype Distribution in the Worldwide Epidemic: Pathogenetic and Therapeutic Implications
J. Virol., October 1, 2007; 81(19): 10209 - 10219.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
N. Lohse, A.-B. E. Hansen, J. Gerstoft, and N. Obel
Improved survival in HIV-infected persons: consequences and perspectives
J. Antimicrob. Chemother., September 1, 2007; 60(3): 461 - 463.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.